Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study - The Lancet www.thelancet.com/journals/lan...
This first-in-human treatment consisting of allogeneic, live stem cells showed no
cell-related adverse effects. The therapy was assessed as sufficiently safe to proceed
with non-staggered enrolment of...
